HB Biotechnologies Corporation
HB Biotechnologies Corporation

Now equity crowdfunding.

Through our equity crowdfunding offering, we aim to create a community of people and a legion of angels who are eager and enthusiastic about joining us on this journey to create a reality beyond dialysis and help patients worldwide who are suffering from heart failure and chronic kidney disease. 

LEARN MORE AND INVEST AT WEFUNDER.COM/FLUIDLOCK

Transforming Kidney Care. Beyond Dialysis.

Millions of People Need Our Help

Millions of People Need Our Help

Millions of People Need Our Help

  • Global number of patients with congestive heart failure and chronic kidney disease is massive.


  • Fluid Lock System is a low-risk tool for fluid management that provides much-needed relief from fluid overload.


  • Market Opportunity: Even a moderate percentage penetration of the market can result in exponential production adoption by millions of willing patients.

Technology + Product = Solution

Millions of People Need Our Help

Millions of People Need Our Help

  • Fluid Lock System is a prescription medical device that changes the paradigm of how fluid is managed by and eliminated from the body -- bypassing the kidneys.


  • Clinical studies have shown that use of superabsorbent polymer technology results in improvements in measures of fluid overload, including body weight, blood pressure, ability to breathe, endurance, heart failure classification, and other quality of life measures.

Safe and Effective Fluid Management

Safe and Effective Fluid Management

Safe and Effective Fluid Management

This breakthrough advancement in cardio renal specialty care helps heart failure and kidney disease patients manage excess fluid. Beyond dialysis.

Freedom from Fluid Overload

Safe and Effective Fluid Management

Safe and Effective Fluid Management

Our Commercialization Journey

About HB Biotechnologies Corporation

HB Biotechnologies is a pre-commercial stage biotechnology company focused on the commercialization of a groundbreaking medical device that provides a low-risk tool for heart failure and kidney disease patients to help manage fluid overload. Beyond dialysis.

 

Sustainable Growth and Success

Currently in our product commercialization journey, the Company now has:

  • Patents in Japan, Canada, all 38 member states of the European Patent Organisation through 2033, and pending USA.
  • Extensive non-clinical and clinical assets that provide a reasonable assurance of safety and effectiveness of the technology for its intended use.
  • Significant manufacturing partnerships with industry titans to produce the commercial product and provide the scale and infrastructure necessary for the longevity of a global brand,


In preparation for global commercial product sales, the Company is now raising capital to manufacture the commercial product and obtain medical device regulatory clearance to market and sell Fluid Lock System to the public.


Recently HB Biotech launched an equity crowdfunding raise on Wefunder to broaden the scope of who can invest in this enterprise. Now, anyone can be part of the solution to bring this life-changing, market-altering medical product to the people who need it -- and experience the benefits of company ownership.

Now equity crowdfunding.

Through our equity crowdfunding offering, we aim to create a community of people and a legion of angels who are eager and enthusiastic about joining us on this journey to create a reality beyond dialysis and help patients worldwide who are suffering from heart failure and chronic kidney disease. 

LEARN MORE AND INVEST AT WEFUNDER.COM/FLUIDLOCK

INVESTOR DECK :: Fluid Lock System by HB Biotech

Download PDF

Fluid Lock System :: Whitepaper Summary of Clinical Results

Download PDF

Let's Connect.

We look forward to speaking with you.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HB Biotechnologies Corporation

contact@hb-biotechnologies.com

Join Us Online

Testing the Waters Legal Disclosure

HB Biotechnologies Corporation is 'testing the waters' to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited. If sent, it will not be accepted. No offer to buy securities will be accepted. No part of the purchase price will be received until a Form C is filed and only through Wefunder’s platform. Any indication of interest involves no obligation or commitment of any kind. 


Home of the Community Round, Wefunder is a Public Benefit Corporation that makes it possible for the general public to invest in startups for as little as $100. Wefunder means Wefunder Inc and its wholly owned subsidiaries: Wefunder Advisors LLC and Wefunder Portal LLC. Wefunder Portal LLC is a member of the Financial Industry Regulatory Authority (FINRA). 


To learn more about the equity crowdfunding offering from HB Biotechnologies Corporation, visit https://wefunder.com/fluidlock  

Forward Looking Statement

This informational website contains statements that are or may be forward-looking statements, including statements that relate to the Company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future.   


Forward-looking statements or information typically contain statements with words such as "anticipate", "believe", "expect", "plan", "intend", "estimate", "propose", "project" or similar words suggesting future outcomes or statements regarding an outlook. Forward-looking statements or information on this website include, but are not limited to the Company’s current focus, revenue goals, and the benefits on the Company of launching new technology.  Forward-looking statements or information is based on several factors and assumptions which have been used to develop such statements and information, but which may prove to be incorrect. Although HB Biotechnologies Corporation believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because the Company can give no assurance that such expectations will prove to be correct.

Copyright © HB Biotechnologies Corporation

P.O. BOX 563 village station, new york, nY 10014

All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept